Tekmira Pharmaceuticals Corp (TKMR) 18.48 $TKMR
Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...
'Mad Money' Lightning Round: I Still Want to Own Freeport-McMoRan
at The Street - Sat Sep 06, 5:00AM CDT
Cramer likes Take-Two Interactive over Activision Blizzard and if you wanted Tekmira Pharmaceuticals you're too late.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.
J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.
Glaxo Up on Accelerated Ebola Vaccine Development Process - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:50PM CDT
Glaxo's Ebola vaccine development process has been fast-tracked by an international consortium.
Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK
PR Newswire - Tue Sep 02, 8:00AM CDT
Today, Analysts Review released its research reports regarding WellPoint Inc. (NYSE: WLP), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Zoetis Inc. (NYSE: ZTS), Sanofi SA (NYSE: SNY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6142-100free.
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 29, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Fast Money' Recap: When Is the Next Market Correction?
at The Street - Fri Aug 29, 4:00AM CDT
The trading panel discussed when the market will pull back, cyber attacks and the company making Apple's sapphire screens.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Surging Today
at The Street - Thu Aug 28, 10:12AM CDT
Tekmira Pharmaceuticals (TKMR) surged Thursday as takeover talks swirl around the Vancouver-based biotech company.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Gaining Today
at The Street - Thu Aug 21, 9:30AM CDT
Monkeys sickened by Marburg virus, an Ebola relative that kills in the same way and is equally as fatal, survived the disease after being treated with its experimental drug.
Tekmira Pharmaceuticals (TKMR) Is Today's Dead Cat Bounce Stock
at The Street - Thu Aug 21, 8:45AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate
The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Tekmira's Lipid Nanoparticle (LNP) Technology Targeting Marburg Virus Highlighted in Scientific Publication
GlobeNewswire - Wed Aug 20, 1:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle (LNP) technology.
5 Stocks Jumping on Unusual Volume
at The Street - Tue Aug 19, 5:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today
at The Street - Mon Aug 18, 12:29PM CDT
Tekmira Pharmaceuticals (TKMR) shares are up double digits after having coverage initiated with an 'outperform' rating and $25 price target by analysts at Leerink.
Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...
'Mad Money' Lightning Round: I Still Want to Own Freeport-McMoRan
at The Street - Sat Sep 06, 5:00AM CDT
Cramer likes Take-Two Interactive over Activision Blizzard and if you wanted Tekmira Pharmaceuticals you're too late.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.
J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.
Glaxo Up on Accelerated Ebola Vaccine Development Process - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:50PM CDT
Glaxo's Ebola vaccine development process has been fast-tracked by an international consortium.
Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK
PR Newswire - Tue Sep 02, 8:00AM CDT
Today, Analysts Review released its research reports regarding WellPoint Inc. (NYSE: WLP), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Zoetis Inc. (NYSE: ZTS), Sanofi SA (NYSE: SNY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6142-100free.
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 29, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Fast Money' Recap: When Is the Next Market Correction?
at The Street - Fri Aug 29, 4:00AM CDT
The trading panel discussed when the market will pull back, cyber attacks and the company making Apple's sapphire screens.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Surging Today
at The Street - Thu Aug 28, 10:12AM CDT
Tekmira Pharmaceuticals (TKMR) surged Thursday as takeover talks swirl around the Vancouver-based biotech company.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Gaining Today
at The Street - Thu Aug 21, 9:30AM CDT
Monkeys sickened by Marburg virus, an Ebola relative that kills in the same way and is equally as fatal, survived the disease after being treated with its experimental drug.
Tekmira Pharmaceuticals (TKMR) Is Today's Dead Cat Bounce Stock
at The Street - Thu Aug 21, 8:45AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate
The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Tekmira's Lipid Nanoparticle (LNP) Technology Targeting Marburg Virus Highlighted in Scientific Publication
GlobeNewswire - Wed Aug 20, 1:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle (LNP) technology.
5 Stocks Jumping on Unusual Volume
at The Street - Tue Aug 19, 5:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today
at The Street - Mon Aug 18, 12:29PM CDT
Tekmira Pharmaceuticals (TKMR) shares are up double digits after having coverage initiated with an 'outperform' rating and $25 price target by analysts at Leerink.
